Prasterone

證據等級: L5

預測適應症: 10 個

Prasterone: From No Approved Indication to Heparin Cofactor 2 Deficiency

One-Sentence Summary

Prasterone (DHEA, DrugBank DB01708) is not currently marketed in this jurisdiction and has no on-file approved indication, so its original clinical use cannot be established from available data. The TxGNN model's top-ranked prediction points to Heparin Cofactor 2 Deficiency, but this signal is supported by 0 clinical trials and 0 publications, and the proposed mechanism plausibly runs in the wrong direction — androgenic steroids are generally associated with a procoagulant, not anticoagulant, profile. This candidate should be treated as speculative until independent mechanistic or clinical evidence emerges.

Quick Overview

Item	Content
Original Indication	Not on record — drug is not marketed in this market, no approved indication text available
Predicted New Indication	Heparin Cofactor 2 Deficiency
TxGNN Prediction Score	99.99%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Prasterone. Based on known information, Prasterone is a naturally occurring adrenal precursor steroid that is metabolized into androgens and estrogens; it has not been established as approved therapy in this market, so its clinical efficacy profile here is undocumented.

Heparin cofactor 2 (HCII) deficiency is a rare hereditary condition in which reduced activity of an anticoagulant plasma protein raises the risk of venous thrombosis. A therapeutically useful agent for this condition would need to support anticoagulant activity or otherwise reduce thrombotic tendency. The evidence pack's own mechanistic assessment flags a direction problem: androgenic/DHEA-related compounds are more commonly reported in the literature as having a procoagulant association (e.g., elevated thrombophilia risk in high-androgen states such as PCOS, cited under a related predicted indication in this same pack) rather than a protective one.

Taken together, the TxGNN score most likely reflects proximity between DHEA-related nodes and coagulation-pathway nodes in the knowledge graph, rather than a validated therapeutic relationship. Without any clinical trial or literature confirmation, and with a plausible mechanistic contradiction, this prediction should be treated as a hypothesis-generating signal only, not a repurposing lead ready for evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

(Note: the underlying data pack flags the TFDA/regulatory package insert as a Blocking data gap — this must be resolved before any safety-based go/no-go decision.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Heparin Cofactor 2 Deficiency) has no clinical trial or literature support (L5, purely model-derived), and the proposed mechanism may run counter to the therapeutic need — androgenic activity is more often linked to increased thrombotic risk than to correction of an anticoagulant deficiency. Combined with the absence of MOA data and TFDA/Fimea labeling information, there is insufficient basis to advance this candidate.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data for Prasterone from DrugBank or primary pharmacology sources
Regulatory package insert (warnings, contraindications, DDI) to close the Blocking data gap (DG001)
Preclinical or pharmacodynamic data specifically addressing DHEA's effect on HCII activity/thrombotic risk, to resolve the directional mechanistic concern
If this program continues, consider re-scoping toward scleroderma (rank 7 in the same evidence pack), which reached decision stage S1 with L4 evidence — six cohort/case-control studies consistently show reduced serum DHEA-S in systemic sclerosis patients correlating with disease severity, offering a more coherent (deficiency-replacement) mechanistic rationale than the top-ranked candidate here
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.